Shaohua Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shaohua Zhang has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Song Wu
Department of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China
11 shared publications Anguo Zhao
Department of Urology South China Hospital Medical School Shenzhen University Shenzhen China
6 shared publicationsLei Peng
Department of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen 518116, China
6 shared publicationsRongkang Li
Department of Urology The Second Hospital & Clinical Medical School Lanzhou University Lanzhou China
5 shared publicationsDashi Deng
Department of Urology South China Hospital Medical School Shenzhen University Shenzhen China
4 shared publicationsRui Liang
Department of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen 518116, China
4 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (62) , e77241
An Intravesical Akkermansia muciniphila ‐Based Chemo‐Immunotherapeutic Platform for Bladder Cancer
Bladder cancer (BC) is a highly recurrent urinary malignancy for which current intravesical immunotherapy and chemotherapy are limited by insufficient efficacy, toxicity, excessive inflammation, and drug resistance. The probiotic Akkermansia muciniphila (AKK), known for its ability to modulate immune responses and suppress pathological inflammation, provides a promising immunomodulatory component to address these limitations. Here, an intravesical bacteria‐based chemo‐immunotherapeutic platform is developed by loading doxorubicin (DOX) onto pasteurized AKK modified with F127, yielding AKK‐F127/DOX (AF/D). Compared with free DOX, AF/D more effectively inhibits bladder cancer cell proliferation, migration, and invasion, while inducing apoptosis, ferroptosis, immunogenic cell death, and suppressing the NF‐κB inflammatory pathway. AF/D also promotes dendritic‐cell maturation, pro‐inflammatory cytokine secretion, M1‐like macrophage polarization, antigen cross‐presentation, and tumor‐specific CD8 + T‐cell priming. In orthotopic bladder cancer models, intravesical AF/D shows superior antitumor efficacy and survival benefits over single‐agent treatments, remodels the local immune microenvironment, enhances systemic antigen‐specific CD8 + T‐cell responses in the spleen, and maintains a favorable safety profile. These findings establish AF/D as a promising intravesical chemo‐immunotherapeutic strategy for bladder cancer.
- 17 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (62) , e77241
Open AccessAn Intravesical Akkermansia muciniphila ‐Based Chemo‐Immunotherapeutic Platform for Bladder Cancer
Bladder cancer (BC) is a highly recurrent urinary malignancy for which current intravesical immunotherapy and chemotherapy are limited by insufficient efficacy, toxicity, excessive inflammation, and drug resistance. The probiotic Akkermansia muciniphila (AKK), known for its ability to modulate immune responses and suppress pathological inflammation, provides a promising immunomodulatory component to address these limitations. Here, an intravesical bacteria‐based chemo‐immunotherapeutic platform is developed by loading doxorubicin (DOX) onto pasteurized AKK modified with F127, yielding AKK‐F127/DOX (AF/D). Compared with free DOX, AF/D more effectively inhibits bladder cancer cell proliferation, migration, and invasion, while inducing apoptosis, ferroptosis, immunogenic cell death, and suppressing the NF‐κB inflammatory pathway. AF/D also promotes dendritic‐cell maturation, pro‐inflammatory cytokine secretion, M1‐like macrophage polarization, antigen cross‐presentation, and tumor‐specific CD8 + T‐cell priming. In orthotopic bladder cancer models, intravesical AF/D shows superior antitumor efficacy and survival benefits over single‐agent treatments, remodels the local immune microenvironment, enhances systemic antigen‐specific CD8 + T‐cell responses in the spleen, and maintains a favorable safety profile. These findings establish AF/D as a promising intravesical chemo‐immunotherapeutic strategy for bladder cancer.
- Open Access
- 17 July 2026
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 225, 107613
Localized in-situ nanomedicine synthesis enables copper-mediated cuproptosis for effective bladder cancer therapy
- 17 July 2026
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 225, 107613
Open AccessLocalized in-situ nanomedicine synthesis enables copper-mediated cuproptosis for effective bladder cancer therapy
- 7 November 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (1) , 111175
Exploration of the assessment of clinical decision-making capabilities in Clinical Oncology based on generative large language models
- 7 November 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (1) , 111175
Exploration of the assessment of clinical decision-making capabilities in Clinical Oncology based on generative large language models
- 16 July 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (10) , 7285-7286
Critical Methodological Considerations for Quantifying Non-clinical Drivers of Post-hepatectomy Length of Stay
- 16 July 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (10) , 7285-7286
Critical Methodological Considerations for Quantifying Non-clinical Drivers of Post-hepatectomy Length of Stay
- Open Access
- 26 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (25) , e2502750
Self‐Propelled In Situ Polymerized Nanoparticles Activating the STING Pathway for Enhanced Bladder Cancer Immunotherapy
Bladder cancer, a common malignancy of the urinary tract, presents complex therapeutic challenges, thereby necessitating the exploration of innovative treatment strategies. This study introduces a novel, self‐propelled nanomedicine delivery system that forms nanoparticles within the bladder lumen by co‐infusing dopamine hydrochloride, Mn 2+ , cGAMP, and urease into the bladder to initiate in situ polymerization. The resulting Mn‐cGAMP@PDA‐urease (DMCU) nanoparticles possess a urease‐modified surface, which acts as an engine to generate propulsive force by breaking down urea. Consequently, this process enhances nanoparticle retention in the bladder mucosa and facilitates efficient drug delivery. The self‐assembled nanoparticles activate the STING pathway, promoting dendritic cell maturation and activation of T cells, thereby enhancing anti‐tumor immune responses. These nanoparticles remain in the bladder for an extended period, significantly improving therapeutic efficacy by sustaining drug release and reducing adverse side effects. In vivo, experiments using a mouse orthotopic model of bladder cancer demonstrate that the DMCU system enhances tumor suppression and immune activation compared with conventional therapies. This novel approach integrates nanotechnology with immunomodulation to address chemotherapy resistance and improve therapeutic efficacy.
- 26 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (25) , e2502750
Open AccessSelf‐Propelled In Situ Polymerized Nanoparticles Activating the STING Pathway for Enhanced Bladder Cancer Immunotherapy
Bladder cancer, a common malignancy of the urinary tract, presents complex therapeutic challenges, thereby necessitating the exploration of innovative treatment strategies. This study introduces a novel, self‐propelled nanomedicine delivery system that forms nanoparticles within the bladder lumen by co‐infusing dopamine hydrochloride, Mn 2+ , cGAMP, and urease into the bladder to initiate in situ polymerization. The resulting Mn‐cGAMP@PDA‐urease (DMCU) nanoparticles possess a urease‐modified surface, which acts as an engine to generate propulsive force by breaking down urea. Consequently, this process enhances nanoparticle retention in the bladder mucosa and facilitates efficient drug delivery. The self‐assembled nanoparticles activate the STING pathway, promoting dendritic cell maturation and activation of T cells, thereby enhancing anti‐tumor immune responses. These nanoparticles remain in the bladder for an extended period, significantly improving therapeutic efficacy by sustaining drug release and reducing adverse side effects. In vivo, experiments using a mouse orthotopic model of bladder cancer demonstrate that the DMCU system enhances tumor suppression and immune activation compared with conventional therapies. This novel approach integrates nanotechnology with immunomodulation to address chemotherapy resistance and improve therapeutic efficacy.
- 3 February 2025
- Published by Wiley in Advanced Therapeutics
- Vol. 8 (3)
The Role of Copper Ions in Mediating the Anti‐Cancer Effects Using Nanomaterials
Copper plays a pivotal role in human physiology, particularly in oncology, acting both as a facilitator of progression and also as a potential avenue for advanced therapeutic approaches. Maintaining copper homeostasis is crucial. The dysregulation of copper homeostasis is implicated in tumor growth through its involvement in critical processes of angiogenesis, proliferation, and metastasis. The elevation in copper level in the tumor microenvironment (TME) activates oncogenic pathways to drive the neovascularization and sustained growth of malignancies. However, the same reliance on copper offers a unique weakness that can be leveraged for innovative therapeutic interventions. The recent advances in nanomedicine enable the synthesis of nanostructures that can help modulate the level of copper with precision offering multifaceted approaches for copper‐based cancer therapy with controlled release mechanism, optimized structures to induce cuproptosis, selective eradication of cancer cells with minimum and systemic toxicity. This review explores the dual role of copper in cancer biology, emphasizing its contribution to the progression of tumors and its emerging application in targeted cancer therapy. The review also highlights the potential of nanostructures in harnessing copper‐based therapies and their transformative potential from bench to bed side with novel, highly effective, and clinical safety.
- 3 February 2025
- Published by Wiley in Advanced Therapeutics
- Vol. 8 (3)
The Role of Copper Ions in Mediating the Anti‐Cancer Effects Using Nanomaterials
Copper plays a pivotal role in human physiology, particularly in oncology, acting both as a facilitator of progression and also as a potential avenue for advanced therapeutic approaches. Maintaining copper homeostasis is crucial. The dysregulation of copper homeostasis is implicated in tumor growth through its involvement in critical processes of angiogenesis, proliferation, and metastasis. The elevation in copper level in the tumor microenvironment (TME) activates oncogenic pathways to drive the neovascularization and sustained growth of malignancies. However, the same reliance on copper offers a unique weakness that can be leveraged for innovative therapeutic interventions. The recent advances in nanomedicine enable the synthesis of nanostructures that can help modulate the level of copper with precision offering multifaceted approaches for copper‐based cancer therapy with controlled release mechanism, optimized structures to induce cuproptosis, selective eradication of cancer cells with minimum and systemic toxicity. This review explores the dual role of copper in cancer biology, emphasizing its contribution to the progression of tumors and its emerging application in targeted cancer therapy. The review also highlights the potential of nanostructures in harnessing copper‐based therapies and their transformative potential from bench to bed side with novel, highly effective, and clinical safety.
- 23 December 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (3) , 1694-1695
Critical Insights on the Clinical and Technical Limitations of AI-Assisted Recurrent Laryngeal Nerve Recognition in Esophageal Surgery
- 23 December 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (3) , 1694-1695
Critical Insights on the Clinical and Technical Limitations of AI-Assisted Recurrent Laryngeal Nerve Recognition in Esophageal Surgery
- Open Access
- 6 December 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (5) , 3305-3306
Expanding the horizons of OpenAI's Sora: Unleashing potential in urology
- 6 December 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (5) , 3305-3306
Open AccessExpanding the horizons of OpenAI's Sora: Unleashing potential in urology
- 6 September 2024
- Published by Elsevier in European Urology
- Vol. 86 (6) , e154
Re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20–6
- 6 September 2024
- Published by Elsevier in European Urology
- Vol. 86 (6) , e154
Re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20–6
- Open Access
- 15 July 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (30)
Bacterial outer membrane vesicle nanorobot
Autonomous nanorobots represent an advanced tool for precision therapy to improve therapeutic efficacy. However, current nanorobotic designs primarily rely on inorganic materials with compromised biocompatibility and limited biological functions. Here, we introduce enzyme-powered bacterial outer membrane vesicle (OMV) nanorobots. The immobilized urease on the OMV membrane catalyzes the decomposition of bioavailable urea, generating effective propulsion for nanorobots. This OMV nanorobot preserves the unique features of OMVs, including intrinsic biocompatibility, immunogenicity, versatile surface bioengineering for desired biofunctionalities, capability of cargo loading and protection. We present OMV-based nanorobots designed for effective tumor therapy by leveraging the membrane properties of OMVs. These involve surface bioengineering of robotic body with cell-penetrating peptide for tumor targeting and penetration, which is further enhanced by active propulsion of nanorobots. Additionally, OMV nanorobots can effectively safeguard the loaded gene silencing tool, small interfering RNA (siRNA), from enzymatic degradation. Through systematic in vitro and in vivo studies using a rodent model, we demonstrate that these OMV nanorobots substantially enhanced siRNA delivery and immune stimulation, resulting in the utmost effectiveness in tumor suppression when juxtaposed with static groups, particularly evident in the orthotopic bladder tumor model. This OMV nanorobot opens an inspiring avenue to design advanced medical robots with expanded versatility and adaptability, broadening their operation scope in practical biomedical domains.
- 15 July 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (30)
Open AccessBacterial outer membrane vesicle nanorobot
Autonomous nanorobots represent an advanced tool for precision therapy to improve therapeutic efficacy. However, current nanorobotic designs primarily rely on inorganic materials with compromised biocompatibility and limited biological functions. Here, we introduce enzyme-powered bacterial outer membrane vesicle (OMV) nanorobots. The immobilized urease on the OMV membrane catalyzes the decomposition of bioavailable urea, generating effective propulsion for nanorobots. This OMV nanorobot preserves the unique features of OMVs, including intrinsic biocompatibility, immunogenicity, versatile surface bioengineering for desired biofunctionalities, capability of cargo loading and protection. We present OMV-based nanorobots designed for effective tumor therapy by leveraging the membrane properties of OMVs. These involve surface bioengineering of robotic body with cell-penetrating peptide for tumor targeting and penetration, which is further enhanced by active propulsion of nanorobots. Additionally, OMV nanorobots can effectively safeguard the loaded gene silencing tool, small interfering RNA (siRNA), from enzymatic degradation. Through systematic in vitro and in vivo studies using a rodent model, we demonstrate that these OMV nanorobots substantially enhanced siRNA delivery and immune stimulation, resulting in the utmost effectiveness in tumor suppression when juxtaposed with static groups, particularly evident in the orthotopic bladder tumor model. This OMV nanorobot opens an inspiring avenue to design advanced medical robots with expanded versatility and adaptability, broadening their operation scope in practical biomedical domains.